| 0 (0%) | 01-19 18:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 | 1-year : | 2.02 |
| Resists | First : | 1.56 | Second : | 1.73 |
| Pivot price | 1.49  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.53 |
| MA(100) : | 2.23 |
MA(250) : | 2.53 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 13.9 |
| RSI | RSI(14): 32.3 |
|||
| 52-week | High : | 4.07 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AKBA ] has closed above bottom band by 16.3%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.42 | 1.42 - 1.43 |
| Low: | 1.32 - 1.33 | 1.33 - 1.34 |
| Close: | 1.35 - 1.36 | 1.36 - 1.37 |
Tue, 13 Jan 2026
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha
Tue, 13 Jan 2026
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving Average - Here's Why - MarketBeat
Tue, 06 Jan 2026
New pill tested for rare kidney disease with no approved treatments - Stock Titan
Mon, 05 Jan 2026
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Sun, 04 Jan 2026
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 265 (M) |
| Shares Float | 260 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 49.8 (%) |
| Shares Short | 34,580 (K) |
| Shares Short P.Month | 35,340 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | -7.1 % |
| Operating Margin | 7.5 % |
| Return on Assets (ttm) | 4.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 57 % |
| Gross Profit (p.s.) | 0.7 |
| Sales Per Share | 0.84 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 32 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | -17 |
| PEG Ratio | 0 |
| Price to Book value | 8.5 |
| Price to Sales | 1.6 |
| Price to Cash Flow | 11.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|